"The Effects of Oxytocin on Patients With Borderline Personality Disorder"
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01243658|
Recruitment Status : Recruiting
First Posted : November 18, 2010
Last Update Posted : April 19, 2019
RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).
Secondary objectives :
Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder. Comparison of the effects of Oxytocin on patients with BPD and major depression.
|Condition or disease||Intervention/treatment||Phase|
|Effects of Oxytocin on Borderline Personality Disorder Borderline Personality Disorder||Drug: Oxytocin Other: placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||"The Effects of Oxytocin on Patients With Borderline Personality Disorder"|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||June 2021|
Placebo Comparator: Placebo
- BPD Symptoms [ Time Frame: BPD Symptoms ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01243658
|Contact: Franny B Spengler, Dr.||firstname.lastname@example.org|
|Freiburg, Baden-Würtemberg, Germany, 79104|
|Contact: Franny B Spengler, Dr. 0049-761-20397742 email@example.com|
|Study Director:||Markus Heinrichs, Prof. Dr.||Institut für Psychologie der Univeristät Freiburg|